Hodgkin Lymphoma-Pipeline Review, H2 2015

Hodgkin Lymphoma-Pipeline Review, H2 2015

  • Products Id :- GMDHC7052IDB
  • |
  • Pages: 322
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Hodgkin Lymphoma-Pipeline Review, H2 2015


Global Markets Direct's, 'Hodgkin Lymphoma-Pipeline Review, H2 2015', provides an overview of the Hodgkin Lymphoma's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Hodgkin Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hodgkin Lymphoma and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides a snapshot of the global therapeutic landscape of Hodgkin Lymphoma

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Hodgkin Lymphoma and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Hodgkin Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Hodgkin Lymphoma pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Hodgkin Lymphoma

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Hodgkin Lymphoma pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Hodgkin Lymphoma Overview 9

Therapeutics Development 10

Pipeline Products for Hodgkin Lymphoma-Overview 10

Pipeline Products for Hodgkin Lymphoma-Comparative Analysis 11

Hodgkin Lymphoma-Therapeutics under Development by Companies 12

Hodgkin Lymphoma-Therapeutics under Investigation by Universities/Institutes 15

Hodgkin Lymphoma-Pipeline Products Glance 16

Late Stage Products 16

Clinical Stage Products 17

Early Stage Products 18

Unknown Stage Products 19

Hodgkin Lymphoma-Products under Development by Companies 20

Hodgkin Lymphoma-Products under Investigation by Universities/Institutes 24

Hodgkin Lymphoma-Companies Involved in Therapeutics Development 25

4SC AG 25

Acetylon Pharmaceuticals, Inc. 26

Actinium Pharmaceuticals, Inc. 27

ADC Therapeutics Sarl 28

Affimed Therapeutics AG 29

Aptose Biosciences Inc. 30

Arbutus Biopharma Corporation 31

AVEO Pharmaceuticals, Inc. 32

Bellicum Pharmaceuticals, Inc. 33

Biogenomics Limited 34

Bristol-Myers Squibb Company 35

Celgene Corporation 36

Cell Medica Limited 37

Cellular Biomedicine Group, Inc. 38

Constellation Pharmaceuticals, Inc. 39

Curis, Inc. 40

Gamida Cell Ltd. 41

Gilead Sciences, Inc. 42

Incyte Corporation 43

Johnson & Johnson 44

Merck & Co., Inc. 45

Millennium Pharmaceuticals, Inc. 46

Mirati Therapeutics Inc. 47

Molecular Templates Inc. 48

NantKwest, Inc. 49

Novartis AG 50

Ono Pharmaceutical Co., Ltd. 51

Pfizer Inc. 52

Pharmacyclics, Inc. 53

Philogen S.p.A. 54

Seattle Genetics, Inc. 55

Selvita SA 56

Sigma-Tau S.p.A. 57

Spectrum Pharmaceuticals, Inc. 58

Stemline Therapeutics, Inc. 59

Syndax Pharmaceuticals, Inc. 60

TG Therapeutics, Inc. 61

Theravectys SA 62

Hodgkin Lymphoma-Therapeutics Assessment 63

Assessment by Monotherapy Products 63

Assessment by Target 64

Assessment by Mechanism of Action 69

Assessment by Route of Administration 73

Assessment by Molecule Type 75

Drug Profiles 77

abexinostat hydrochloride-Drug Profile 77

acalisib-Drug Profile 80

ADCT-301-Drug Profile 81

AFM-13-Drug Profile 82

Alocrest-Drug Profile 83

aNK Program-Drug Profile 85

APTO-253-Drug Profile 88

azacitidine-Drug Profile 90

BMS-986016-Drug Profile 94

BPX-501-Drug Profile 95

brentuximab vedotin-Drug Profile 97

CBM-C30.1-Drug Profile 103

Cell Therapy to Target CD30 for Hodgkin and Non-Hodgkin Lymphomas-Drug Profile 104

Cell Therapy to Target GM-CSF for Hodgkin Lymphoma and Chronic Lymphocytic Leukemia-Drug Profile 105

Cell Therapy to Target LMP, BARF-1 and EBNA1 for EBV Associated Cancers and Infection-Drug Profile 106

Cell Therapy to Target LMP-1 and LMP-2 for Oncology and Infectious Diseases-Drug Profile 107

Cell Therapy to Target NY-ESO-1, MAGEA4, PRAME, Survivin and Synovial Sarcoma X for Oncology-Drug Profile 108

CMD-003-Drug Profile 109

CPI-0610-Drug Profile 111

CUDC-907-Drug Profile 112

Dendritic Cell Therapy for Hodgkin Lymphoma and Non-Hodgkin Lymphoma-Drug Profile 114

Dendritic Cell Therapy for Oncology-Drug Profile 115

entinostat-Drug Profile 116

Ferritarg-Drug Profile 120

ficlatuzumab-Drug Profile 121

haNK Program-Drug Profile 124

INCB-39110-Drug Profile 126

INCB-40093-Drug Profile 128

Indimitecan-Drug Profile 129

Indotecan hydrochloride-Drug Profile 130

interferon alfa-2b (recombinant)-Drug Profile 132

Iomab-B-Drug Profile 133

ixazomib citrate-Drug Profile 135

JNJ-40346527-Drug Profile 139

MK-2206-Drug Profile 141

mocetinostat-Drug Profile 144

Monoclonal Antibodies to Inhibit PD-1/PD-L1 for Hematological Malignancies-Drug Profile 147

Monoclonal Antibody Conjugate to Target CD45 for Oncology-Drug Profile 148

NiCord-Drug Profile 149

nivolumab-Drug Profile 150

NSC-678515-Drug Profile 157

panobinostat-Drug Profile 158

pembrolizumab-Drug Profile 164

pevonedistat hydrochloride-Drug Profile 173

procarbazine hydrochloride-Drug Profile 175

radretumab-Drug Profile 176

Recombinant Proteins for Melanoma and Hodgkin's Lymphoma-Drug Profile 178

resminostat-Drug Profile 179

ricolinostat-Drug Profile 184

RP-323-Drug Profile 186

ruxolitinib phosphate-Drug Profile 187

SEL-24B489-Drug Profile 192

SL-101-Drug Profile 193

SL-501-Drug Profile 194

temsirolimus-Drug Profile 195

TGR-1202-Drug Profile 197

TKM-PLK1-Drug Profile 199

Vaccine for EBV Associated Cancer-Drug Profile 201

Hodgkin Lymphoma-Recent Pipeline Updates 202

Hodgkin Lymphoma-Dormant Projects 299

Hodgkin Lymphoma-Discontinued Products 302

Hodgkin Lymphoma-Product Development Milestones 303

Featured News & Press Releases 303

Appendix 317

Methodology 317

Coverage 317

Secondary Research 317

Primary Research 317

Expert Panel Validation 317

Contact Us 317

Disclaimer 318

List of Tables

Number of Products under Development for Hodgkin Lymphoma, H2 2015 14

Number of Products under Development for Hodgkin Lymphoma-Comparative Analysis, H2 2015 15

Number of Products under Development by Companies, H2 2015 17

Number of Products under Development by Companies, H2 2015 (Contd..1) 18

Number of Products under Investigation by Universities/Institutes, H2 2015 19

Comparative Analysis by Late Stage Development, H2 2015 20

Comparative Analysis by Clinical Stage Development, H2 2015 21

Comparative Analysis by Early Stage Development, H2 2015 22

Comparative Analysis by Unknown Stage Development, H2 2015 23

Products under Development by Companies, H2 2015 24

Products under Development by Companies, H2 2015 (Contd..1) 25

Products under Development by Companies, H2 2015 (Contd..2) 26

Products under Development by Companies, H2 2015 (Contd..3) 27

Products under Investigation by Universities/Institutes, H2 2015 28

Hodgkin Lymphoma-Pipeline by 4SC AG, H2 2015 29

Hodgkin Lymphoma-Pipeline by Acetylon Pharmaceuticals, Inc., H2 2015 30

Hodgkin Lymphoma-Pipeline by Actinium Pharmaceuticals, Inc., H2 2015 31

Hodgkin Lymphoma-Pipeline by ADC Therapeutics Sarl, H2 2015 32

Hodgkin Lymphoma-Pipeline by Affimed Therapeutics AG, H2 2015 33

Hodgkin Lymphoma-Pipeline by Aptose Biosciences Inc., H2 2015 34

Hodgkin Lymphoma-Pipeline by Arbutus Biopharma Corporation, H2 2015 35

Hodgkin Lymphoma-Pipeline by AVEO Pharmaceuticals, Inc., H2 2015 36

Hodgkin Lymphoma-Pipeline by Bellicum Pharmaceuticals, Inc., H2 2015 37

Hodgkin Lymphoma-Pipeline by Biogenomics Limited, H2 2015 38

Hodgkin Lymphoma-Pipeline by Bristol-Myers Squibb Company, H2 2015 39

Hodgkin Lymphoma-Pipeline by Celgene Corporation, H2 2015 40

Hodgkin Lymphoma-Pipeline by Cell Medica Limited, H2 2015 41

Hodgkin Lymphoma-Pipeline by Cellular Biomedicine Group, Inc., H2 2015 42

Hodgkin Lymphoma-Pipeline by Constellation Pharmaceuticals, Inc., H2 2015 43

Hodgkin Lymphoma-Pipeline by Curis, Inc., H2 2015 44

Hodgkin Lymphoma-Pipeline by Gamida Cell Ltd., H2 2015 45

Hodgkin Lymphoma-Pipeline by Gilead Sciences, Inc., H2 2015 46

Hodgkin Lymphoma-Pipeline by Incyte Corporation, H2 2015 47

Hodgkin Lymphoma-Pipeline by Johnson & Johnson, H2 2015 48

Hodgkin Lymphoma-Pipeline by Merck & Co., Inc., H2 2015 49

Hodgkin Lymphoma-Pipeline by Millennium Pharmaceuticals, Inc., H2 2015 50

Hodgkin Lymphoma-Pipeline by Mirati Therapeutics Inc., H2 2015 51

Hodgkin Lymphoma-Pipeline by Molecular Templates Inc., H2 2015 52

Hodgkin Lymphoma-Pipeline by NantKwest, Inc., H2 2015 53

Hodgkin Lymphoma-Pipeline by Novartis AG, H2 2015 54

Hodgkin Lymphoma-Pipeline by Ono Pharmaceutical Co., Ltd., H2 2015 55

Hodgkin Lymphoma-Pipeline by Pfizer Inc., H2 2015 56

Hodgkin Lymphoma-Pipeline by Pharmacyclics, Inc., H2 2015 57

Hodgkin Lymphoma-Pipeline by Philogen S.p.A., H2 2015 58

Hodgkin Lymphoma-Pipeline by Seattle Genetics, Inc., H2 2015 59

Hodgkin Lymphoma-Pipeline by Selvita SA, H2 2015 60

Hodgkin Lymphoma-Pipeline by Sigma-Tau S.p.A., H2 2015 61

Hodgkin Lymphoma-Pipeline by Spectrum Pharmaceuticals, Inc., H2 2015 62

Hodgkin Lymphoma-Pipeline by Stemline Therapeutics, Inc., H2 2015 63

Hodgkin Lymphoma-Pipeline by Syndax Pharmaceuticals, Inc., H2 2015 64

Hodgkin Lymphoma-Pipeline by TG Therapeutics, Inc., H2 2015 65

Hodgkin Lymphoma-Pipeline by Theravectys SA, H2 2015 66

Assessment by Monotherapy Products, H2 2015 67

Number of Products by Stage and Target, H2 2015 69

Number of Products by Stage and Mechanism of Action, H2 2015 74

Number of Products by Stage and Route of Administration, H2 2015 78

Number of Products by Stage and Molecule Type, H2 2015 80

Hodgkin Lymphoma Therapeutics-Recent Pipeline Updates, H2 2015 206

Hodgkin Lymphoma-Dormant Projects, H2 2015 303

Hodgkin Lymphoma-Dormant Projects (Contd..1), H2 2015 304

Hodgkin Lymphoma-Dormant Projects (Contd..2), H2 2015 305

Hodgkin Lymphoma-Discontinued Products, H2 2015 306

List of Figures

Number of Products under Development for Hodgkin Lymphoma, H2 2015 14

Number of Products under Development for Hodgkin Lymphoma-Comparative Analysis, H2 2015 15

Number of Products under Development by Companies, H2 2015 16

Number of Products under Investigation by Universities/Institutes, H2 2015 19

Comparative Analysis by Late Stage Development, H2 2015 20

Comparative Analysis by Clinical Stage Development, H2 2015 21

Comparative Analysis by Early Stage Products, H2 2015 22

Assessment by Monotherapy Products, H2 2015 67

Number of Products by Top 10 Targets, H2 2015 68

Number of Products by Stage and Top 10 Targets, H2 2015 68

Number of Products by Top 10 Mechanism of Actions, H2 2015 73

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 73

Number of Products by Routes of Administration, H2 2015 77

Number of Products by Stage and Routes of Administration, H2 2015 77

Number of Products by Top 10 Molecule Types, H2 2015 79

Number of Products by Stage and Top 10 Molecule Types, H2 2015 79

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com


Acetylon Pharmaceuticals, Inc.

Actinium Pharmaceuticals, Inc.

ADC Therapeutics Sarl

Affimed Therapeutics AG

Aptose Biosciences Inc.

Arbutus Biopharma Corporation

AVEO Pharmaceuticals, Inc.

Bellicum Pharmaceuticals, Inc.

Biogenomics Limited

Bristol-Myers Squibb Company

Celgene Corporation

Cell Medica Limited

Cellular Biomedicine Group, Inc.

Constellation Pharmaceuticals, Inc.

Curis, Inc.

Gamida Cell Ltd.

Gilead Sciences, Inc.

Incyte Corporation

Johnson & Johnson

Merck & Co., Inc.

Millennium Pharmaceuticals, Inc.

Mirati Therapeutics Inc.

Molecular Templates Inc.

NantKwest, Inc.

Novartis AG

Ono Pharmaceutical Co., Ltd.

Pfizer Inc.

Pharmacyclics, Inc.

Philogen S.p.A.

Seattle Genetics, Inc.

Selvita SA

Sigma-Tau S.p.A.

Spectrum Pharmaceuticals, Inc.

Stemline Therapeutics, Inc.

Syndax Pharmaceuticals, Inc.

TG Therapeutics, Inc.

Theravectys SA

Hodgkin Lymphoma Therapeutic Products under Development, Key Players in Hodgkin Lymphoma Therapeutics, Hodgkin Lymphoma Pipeline Overview, Hodgkin Lymphoma Pipeline, Hodgkin Lymphoma Pipeline Assessment

select a license

Single User License
USD 2000 INR 132420
Site License
USD 4000 INR 264840
Corporate User License
USD 6000 INR 397260



The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...

Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@] kenresearch.com